MedTrace Logo

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

NCT00185302 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-12-14

No results posted yet for this study

Summary

Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma

Conditions

Interventions

DRUG

Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)

MS-275, 3 mg on Days 1 and 15 of a 4-week cycle

DRUG

Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)

MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2006-07-31
Completion
2006-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185302 on ClinicalTrials.gov